-
公开(公告)号：CA3089762A1
公开(公告)日：2019-08-01
申请号：CA3089762
申请日：2019-01-28
Applicant: MERCK PATENT GMBH , VERTEX PHARMA
Inventor： BAYLY ANDREW , BLEICH MATTHEW , CHARRIER JEAN-DAMIEN , DODD JAMES , DURRANT STEVEN , ENO MEREDITH SUZANNE , ETXEBARRIA I JARDI GORKA , EVERITT SIMON , FRAYSSE DAMIEN , KELLY SHAZIA , KNEGTEL RONALD , MOCHALKIN IGOR , MORTIMORE MICHAEL , NORTH KIRI , PORICHIS FILIPPOS , PULLIN ROBERT , RUTHERFORD ALISTAIR , STORCK PIERRE-HENRI , TWIN HEATHER CLARE , XIAO YUFANG
IPC: C07D487/04 , A61K31/395 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61P35/00 , C07D519/00
Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
-
公开(公告)号：CY1120232T1
公开(公告)日：2019-07-10
申请号：CY181100515
申请日：2018-05-18
Applicant: VERTEX PHARMA
Inventor： AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61K31/495 , A61P35/00
Abstract: Ηπαρούσαεφεύρεσηαναφέρεταισεενώσειςχρήσιμεςωςαναστολείςκινάσηςπρωτεΐνης ATR. Ηεφεύρεσηαναφέρεται, επίσης, σεφαρμακευτικώςαποδεκτέςσυνθέσεις, οιοποίεςπεριέχουντιςενώσειςαυτήςτηςεφεύρεσης, μεθόδουςθεραπευτικήςαγωγήςδιαφόρωνασθενειών, διαταραχώνκαικαταστάσεωνμεχρήσητωνενώσεωναυτήςτηςεφεύρεσης, διαδικασίεςγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσης, ενδιάμεσαγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσηςκαιμεθόδουςχρήσηςτωνενώσεωνσε in vitro εφαρμογές, όπωςη μελέτηκινασώνσεβιολογικάκαιπαθολογικάφαινόμενα, ημελέτηοδώνμεταγωγήςενδοκυτταρικώνσημάτωνπουδιαμεσολαβείταιαπότέτοιεςκινάσεςκαιη συγκριτικήαξιολόγησηνέωναναστολέωνκινασών. Οιενώσειςαυτήςτηςεφεύρεσηςέχουντύπο (I) ήέναφαρμακευτικώςαποδεκτόάλας, όπουοιμεταβλητέςείναιόπωςορίζονταιστοπαρόν. Επιπλέον, οιενώσειςαυτήςτηςεφεύρεσηςέχουντύπο (Ι-Α) ήέναφαρμακευτικώςαποδεκτόάλας, όπουοιμεταβλητέςείναιόπωςορίζονταιστοπαρόν.
-
公开(公告)号：ME03036B
公开(公告)日：2018-10-20
申请号：MEP2018134
申请日：2013-12-06
Applicant: VERTEX PHARMA
Inventor： AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: A61K31/495 , A61P35/00 , C07D487/04
-
公开(公告)号：DK2941432T3
公开(公告)日：2018-06-14
申请号：DK13811716
申请日：2013-12-06
Applicant: VERTEX PHARMA
Inventor： AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61K31/495 , A61P35/00
-
公开(公告)号：HK1217190A1
公开(公告)日：2016-12-30
申请号：HK16105069
申请日：2016-05-04
Applicant: VERTEX PHARMA
Inventor： AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D20060101 , A61K20060101 , A61P20060101
-
Patent Agency Ranking
公开(公告)号：AU2013355124A1
公开(公告)日：2015-06-18
申请号：AU2013355124
申请日：2013-12-06
Applicant: VERTEX PHARMA
Inventor： AHMAD NADIA , BOYALL DEAN , CHARRIER JEAN-DAMIEN , DAVIS CHRIS , DAVIS REBECCA , DURRANT STEVEN , ETXEBARRIA I JARDI GORKA , FRAYSSE DAMIEN , JIMENEZ JUAN-MIGUEL , KAY DAVID , KNEGTEL RONALD , MIDDLETON DONALD , ODONNELL MICHAEL , PANESAR MANINDER , PIERARD FRANCOISE , PINDER JOANNE , SHAW DAVID , STORCK PIERRE-HENRI , STUDLEY JOHN , TWIN HEATHER
IPC: C07D487/04 , A61K31/495 , A61P35/00
Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in
-
公开(公告)号：NZ603477A
公开(公告)日：2014-09-26
申请号：NZ60347711
申请日：2011-05-12
Applicant: VERTEX PHARMA
Inventor： STORCK PIERRE-HENRI , KAY DAVID , BINCH HAYLEY MARIE , FANNING LEV TYLER DEWEY , REAPER PHILIP MICHAEL , CHARRIER JEAN-DAMIEN , YOUNG STEPHEN CLINTON , HURLEY DENNIS JAMES , KNEGTEL RONALD MARCELLUS ALPHONSUS , JOSHI PRAMOD , O’DONNELL MICHAEL , CLEVELAND THOMAS , VIRANI ANISA NIZARALI , GROTE MATTHEW PAUL , PINDER JOANNE , DURRANT STEVEN JOHN
IPC: C07D413/14 , A61K31/444 , A61K31/497 , A61P35/00
Abstract: The disclosure relates to pyrazine and pyridine derivatives of formula (I), wherein the variables are as defined in the specification. These compounds are useful as inhibitors of ATR protein kinase involved in cellular responses to DNA damage, and are suitable for treating various diseases, disorders, and conditions that are mediated by the particular protein kinase, particularly suitable for treating cancer selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, and brain cancer. Processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors are also disclosed.
-
公开(公告)号：MX2012013081A
公开(公告)日：2013-05-09
申请号：MX2012013081
申请日：2011-05-12
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , KAY DAVID , JOSHI PRAMOD , YOUNG STEPHEN CLINTON , O'DONNELL MICHAEL , PINDER JOANNE , VIRANI ANISA NIZARALI , REAPER PHILIP MICHAEL , BINCH HAYLEY MARIE , CLEVELAND THOMAS , DURRANT STEVEN JOHN , KNEGTEL RONALD MARCELLUS ALPHONSUS , FANNING LEV TYLER DEWEY , HURLEY DENNIS JAMES , STORCK PIERRE-HENRI , GROTE MATTHEW PAUL
IPC: C07D413/14 , A61K31/444 , A61K31/497 , A61P35/00
Abstract: La presente invención se refiere a compuestos de pirazina y piridina útiles como inhibidores de la proteína cinasa ATR. La invención también se refiere a composiciones farmacéuticamente aceptables que comprenden los compuestos de esta invención; métodos para tratar diversas enfermedades, trastornos y afecciones usando los compuestos de esta invención; procesos para preparar los compuestos de esta invención; intermedios para la preparación de los compuestos de esta invención; y métodos para usar los compuestos en aplicaciones in vitro, tales como el estudio de cinasas en fenómenos biológicos y patológicos; el estudio de vías de transducción de señales intracelulares mediadas por tales cinasas y la evaluación comparativa de nuevos inhibidores de cinasas. Los compuestos de la presente invención tienen la fórmula I donde las variables son tal como se describen en la presente.
-
公开(公告)号：CA2850564A1
公开(公告)日：2013-04-04
申请号：CA2850564
申请日：2012-09-28
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , STORCK PIERRE-HENRI , STUDLEY JOHN , PIERARD FRANCOISE YVONNE THEODORA MARIE , DURRANT STEVEN JOHN , LITTLER BENJAMIN JOSEPH , ANGELL PAUL , HUGHES ROBERT MICHAEL , SIESEL DAVID ANDREW , URBINA ARMANDO , ZWICKER CARL , LOCONTE NICHOLAS , BARDER TIMOTHY
IPC: C07D413/14 , A61K31/497 , A61P35/00
Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-l : wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
-
公开(公告)号：CA2832100A1
公开(公告)日：2012-10-11
申请号：CA2832100
申请日：2012-04-05
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , MACCORMICK SOMHAIRLE , STORCK PIERRE-HENRI , PINDER JOANNE , O'DONNELL MICHAEL EDWARD , KNEGTEL RONALD MARCELLUS ALPHONSUS , YOUNG STEPHEN CLINTON YOUNG , KAY DAVID , REAPER PHILIP MICHAEL , DURRANT STEVEN JOHN , TWIN HEATHER CLARE , DAVIS CHRISTOPHER JOHN
IPC: C07D413/14 , A61K31/497 , A61P35/00
Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I): wherein the variables are as defined herein.
-
-
-
-
-
-
-
-
-
Search Results
80
records
(took 0.024 seconds)
